Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-lea
The Biden administration has allocated $1.4 billion to new COVID-19 vaccines and drugs, as new SARS-CoV-2 variant BA.2.86 has started spreading in the US.
Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the
Patients with the ultra-rare disease CHAPLE now have their first FDA-approved therapy, after the regulator approved Regeneron's pozelimab for people aged one and over with
Regeneron has agreed a $109 million deal to acquire Decibel Therapeutics and its early-stage gene therapy for a form of congenital deafness, several years after forming a
In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 mill
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl